- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07947069
Nebulized Plus Intravenous Versus Intravenous Furosemide in Pulmonary Edema
Effectiveness of Nebulized Plus Intravenous Furosemide Versus Intravenous Furosemide in Treating Pulmonary Edema: A Randomized Controlled Trial
This randomized controlled trial compares intravenous furosemide alone with intravenous plus nebulized furosemide in adults with acute pulmonary edema. The main outcome is the change in peripheral oxygen saturation (SpO2) from baseline, and the secondary outcome is the change in dyspnea severity on a 0-10 visual analogue scale. The trial will test whether adding nebulized furosemide to standard intravenous furosemide gives additional benefit.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Pulmonary edema is a medical emergency in which fluid collects in the alveolar spaces, impairing gas exchange and causing respiratory distress. Intravenous furosemide is the mainstay of treatment but may cause hypotension, electrolyte imbalance and renal dysfunction. Nebulized furosemide delivers the drug directly to the lungs and may improve dyspnea and oxygenation through local effects. Most available studies have tested nebulized furosemide as an alternative to intravenous therapy rather than as an adjunct, so it remains unclear whether the combination offers added benefit over intravenous furosemide alone.
Methods: A randomized controlled trial will be conducted in the Department of Medicine, Federal Government Polyclinic Hospital, Islamabad, over 6 months after ethical approval, using non-probability consecutive sampling. A total of 130 patients (65 per group) will be enrolled. Sample size was calculated with the WHO formula for two means (alpha 0.05, power 80%, SD 1.5, expected difference 0.7) based on Barzegari et al. (2021). After written informed consent, baseline demographics, vital signs, SpO2 and dyspnea VAS score will be recorded. All patients will receive standard initial care with oxygen 6 to 10 L/min by face mask, intravenous nitroglycerin infusion starting at 10 µg/min and intravenous morphine 3 to 5 mg. Patients will be randomized 1:1 using a computer-generated sequence with sequentially numbered, opaque, sealed envelopes. Group A will receive intravenous furosemide 1 mg/kg plus nebulized furosemide 40 mg in 4 ml 0.9% saline, and Group B will receive intravenous furosemide 1 mg/kg alone. SpO2 and dyspnea VAS will be recorded at baseline and at 30, 60 and 120 minutes after intervention.
Statistical analysis: Data will be analyzed in SPSS version 23. Continuous variables will be presented as mean and standard deviation. Between-group comparison of change from baseline in SpO2 and VAS will be done with the independent samples t-test, or the Mann-Whitney U test for non-normal data. Baseline SpO2, baseline dyspnea score, oxygen flow rate, use of nitrates or morphine and underlying cardiac function will be recorded as potential confounders. A p-value below 0.05 will be considered significant.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 4
Contatti e Sedi
Contatto studio
- Nome: Tausif Khan
- Numero di telefono: +923110920949
- Email: mtausifkhan1999@gmail.com
Luoghi di studio
-
-
Islamabad
-
Islamabad, Islamabad, Pakistan, 44000
- Department of Medicine, Federal Government Polyclinic Hospital
-
Investigatore principale:
- Tausif Khan
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Adults aged 18 to 94 years
- Acute shortness of breath within the past 6 hours
- Clinical features of pulmonary edema (tachypnea, use of accessory muscles, crepitations, wheeze, gallop rhythm) with chest X-ray showing bilateral pulmonary infiltrates consistent with pulmonary edema, with or without cardiomegaly, pulmonary vascular congestion, Kerley B lines or pleural effusion
Exclusion Criteria:
- Cardiogenic shock or systolic blood pressure below 90 mm Hg
- Need for intubation, cardiac arrhythmia or liver failure
- COPD or asthma exacerbation
- End-stage renal disease on dialysis
- Allergy to furosemide
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Group A: IV plus nebulized furosemide
Intravenous furosemide 1 mg/kg slow push over 5 minutes plus nebulized furosemide 40 mg diluted in 4 ml 0.9% saline over 15 minutes, in addition to standard initial care (oxygen 6 to 10 L/min by face mask, intravenous nitroglycerin infusion starting at 10 µg/min and intravenous morphine 3 to 5 mg). |
Furosemide 40 mg diluted in 4 ml 0.9% saline given by jet nebulizer over 15 minutes.
Altri nomi:
Furosemide 1 mg/kg given as a slow intravenous push over 5 minutes.
Altri nomi:
|
|
Comparatore attivo: Group B: IV furosemide
Intravenous furosemide 1 mg/kg slow push over 5 minutes, in addition to standard initial care (oxygen 6 to 10 L/min by face mask, intravenous nitroglycerin infusion starting at 10 µg/min and intravenous morphine 3 to 5 mg). |
Furosemide 1 mg/kg given as a slow intravenous push over 5 minutes.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in peripheral oxygen saturation (SpO2)
Lasso di tempo: Baseline, 30, 60 and 120 minutes after intervention (primary comparison at 60 minutes)
|
SpO2 (%) measured with a calibrated pulse oximeter; change from baseline will be compared between groups. |
Baseline, 30, 60 and 120 minutes after intervention (primary comparison at 60 minutes)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in dyspnea severity on Visual Analogue Scale (VAS)
Lasso di tempo: Baseline, 30, 60 and 120 minutes after intervention
|
Patient-rated breathlessness on a 0-10 VAS (0 = no breathlessness, 10 = worst breathlessness); change from baseline will be compared between groups. |
Baseline, 30, 60 and 120 minutes after intervention
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Tausif Khan, MBBS, FCPS Trainee, Federal Government Polyclinic Hospital, Islamabad
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie delle vie respiratorie
- Malattie polmonari
- Disturbi respiratori
- Segni e sintomi, respiratori
- Condizioni patologiche, segni e sintomi
- Segni e sintomi
- Edema polmonare
- Dispnea
- Composti di zolfo
- Prodotti chimici organici
- Amides
- Composti di anilina
- Ammine
- Sulfonamidi
- Sulfanilamides
- Solfoni
- Furosemide
Altri numeri di identificazione dello studio
- FGPC-PGMI-MED-2026-PE01
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .